Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 1998

View Archived Issues

Novel PTK-related technology from Genentech and collaborators

Preclinical pharmacology of ebselen described in depth

ProCyte reports results from U.K. leg ulcer study

Calanolide A well tolerated in phase I trials

Tiazac approved for angina in U.S.

Warner-Lambert presents SAR for potent, nonpeptide HIV protease inhibitor at AIDS conference

Avita gel can now be launched in U.S.

Genetic basis for RP described

Favorable clinical safety, pharmacokinetics and anti-CMV activity reported for 1263W94

Concrete terms of Receptagen-Scitech Genetics merger announced

Gene-based breast cancer test launched in U.S.

Salivary peptide fragment may be useful for oral candidiasis

Algos initiates FDA approval process for MorphiDex

Janssen obtains worldwide license to develop and market norastemizole

E.U. gives stamp of approval to Roche acquisition of Corange

Cytel and Baxter extend xenotransplantation agreement

Early clinical results support potential of ABT-378/ritonavir combination

Another name change for BioDx

Biomet-Merck orthopedic joint venture

Multiple-dose phase I trial of FP-21399 in HIV discussed at AIDS conference

New anti-PCP agent is more potent than pentamidine

PNU-140690: clinical pharmacokinetics and safety after single and multiple doses

Seragen fusion toxin will get priority review

Penederm and Alpharma enter marketing agreement

NIF is neuroprotective in rat model of ischemia

Pharmacokinetics and drug interactions for Fortovase

FddA demonstrates anti-HIV activity at well-tolerated doses in phase I trial

Zestril introduced for new indication in U.K.

CardioGenesis receives EU approval to market cardiovascular device

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...